CHIEF EXECUTIVE OFFICER
Dr David Hughes MEng, DPhil
Dr Hughes joined CN Bio Innovations in 2010 as Head of Engineering, was promoted to Technical Director in 2013 with responsibility for the management of all in-house and collaborative research and development programmes and the contract research services business. Dr Hughes was subsequently promoted to Chief Technology Officer in July 2014 with responsibility for managing the technical programs with the company’s academic and industrial partners. and, in 2018, he was promoted to CEO. During his career at CN Bio, he has secured and overseen the successful delivery of government and pharmaceutical research contracts and research grants totalling more than £2Mi.
Dr Hughes is also Principal Investigator on a $26Mi US Defence Advanced Research Projects Agency (DARPA) contract towards development of human in vitro multi-organ platforms and leads a €4Mi EU FP7 program aimed at developing stem cell derived models of human liver. Before joining CN Bio, he spent three years working in manufacturing and research and development at GlaxoSmithKline. Dr Hughes graduated from the University of Oxford with a Masters in Engineering Science and Doctorate in Chemical Engineering.
CHIEF FINANCIAL OFFICER
Dr Patrick Driscoll ACA, PhD
Dr Driscoll joined CN Bio Innovations in 2017. As Chief Financial Officer, he is responsible for all aspects of the company’s operational, financial, and legal matters.
Dr Driscoll has experience in business, finance, and operational management in Europe and the US. He trained and qualified with Deloitte, working with an array of high-tech and biotech start-ups. Patrick joined CN Bio from Johnson Matthey plc, where he held a number of roles from providing internal audit, advisory and consulting services for manufacturing operations worldwide to operational management of precious metal refineries and commodities trading desks in Europe and North America. Dr Driscoll is an ICAEW Chartered Accountant and holds a PhD in History from the University of Cambridge.
Paul joined CN Bio in August 2018 as Commercial Director bringing his experience in Global Business Development and Sales as the company seeks to meet the demand for the new and exciting products it is able to offer in this sector.
Paul started in sales within the pharmaceutical industry including Regional Management & International Sales Training. He joined an American owned business operating in the complex home care sector leading an MBO team. Paul’s next move was into consultancy specialising in the biotech/healthcare sectors helping companies exploit new and disruptive technologies in global markets, particularly in the US, Japan, China and Europe.
Mrs Maureen Coleman BSc
Mrs Coleman has amassed over 30 years’ experience within the pharmaceutical industry, latterly as VP Global Strategy Development for GlaxoSmithKline. Since 2007 she has been working with a number of investor-backed companies including as founding Chief Executive of NovaThera, a regenerative medicine spin-out from Imperial College London, and as Non-Executive Director and Chairman of life science spin-out companies from Oxford, Kings College Universities and other life science entrepreneurs.
Mrs Coleman is currently Chairman of Parafricta Ltd, a wound care specialist materials company, and CN Bio Innovations – the human organ-on-a-chip technology company whose LiverChip and Quantum B® human liver models are being well received as a disruptive route to liver modelling for Hepatitis B drug discovery and ADME tox testing. She is a founding Director of MedInnovate Ltd, a technology consultancy spanning the healthcare industry, and a founding industry consulting partner at Kinapse Ltd.
Dr David Scales PhD LLM FRCPath
Dr Scales has broad experience in the pharmaceutical, biotech and contract research sectors in senior and non-executive roles. During more than 20 years working for large pharmaceutical companies, Dr Scales’ roles included International VP at GlaxoWellcome overseeing development staff located in the USA, UK, Italy and Japan. During his tenure at GlaxoWellcome he represented the European pharmaceutical Industry and chaired the Safety Committee for the first two International Conferences on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use.
Dr Scales moved into the biotechnology sector in 2000 working as R&D director for Strakan Ltd, Charterhouse Therapeutics Ltd and Antisoma PLC before becoming CEO of Cerogenix Ltd and then GlycoForm Ltd. In January 2013 he joined CN Bio Innovations as Chief Executive. He took on the role as Board advisor to the company in 2016 to then join as Non-Executive Director in 2018. Dr Scales initially trained as a toxicological pathologist, holds three degrees from London University and the Royal Postgraduate Medical School, and is a Fellow of the Royal College of Pathologists.